BillyHoonChangMDPhD

PubMed

• 121 citations
  Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
  Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E Kurtz, Cristina E Tognon
  Cancer Cell. 2022-08-08
• 7 citations
  Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.
  Stephen E Kurtz, Christopher A Eide, Andy Kaempf, Nicola Long, Daniel Bottomly
  Blood Advances. 2022-05-24
• 25 citations
  Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c...
  Lauren Pommert, Eric S Schafer, Jemily Malvar, Nathan Gossai, Ellynore Florendo
  American Journal of Hematology. 2022-05-01

Journal Articles

• Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening  
  Tyner JT, Yang WF, Bankhead III A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM,..., Cancer Res, 1/1/2013
• Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ALL: a Children’s Oncology Group (COG) study  
  Chang B.H., Willis S.G., Stork L., Hunger S.P., Carroll W.L., Camitta B.M., Winick N.J., Druker B.J., & Schultz K.R., British Journal of Haematology, 1/1/2012
• Abnormal developmental control of replication timing domains in pediatric acute lymphoblastic leukemia  
  Ryba T., Battaglia D., Chang B.H., Shirley J.W., Druker B.J., & Gilbert D.M., Genome Res, 1/1/2012
• Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia  
  Bicocca VT, Chang BH, Kharabi Masouleh B, Muschen M, Loriaux MM, Druker BJ, Tyner JW, Cancer Cell, 1/1/2012
• In vitro sensitivity to Dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre B Acute Lymphoblastic Leukemia  
  Glover J., Loriaux M., Tyner J.W., Druker BJ., & Chang B.H., Pediatric Blood and Cancer, 1/28/2011
• Targeting Survivin and p53 in Pediatric Acute Lymphoblastic Leukemia  
  Tyner J.W., Jemal A., Thayer M., Druker B.J., & Chang B.H., Leukemia, 1/1/2011
• RNAi Screen for Rapid Therapeutic Target Identification in Leukemia Patients  
  Tyner J.W., Deininger M.W., Loriaux M.M., Chang B.H., Gotlib J.R., Willis S.G., Erickson H., Kovacsovics T., O’Hare T., Heinrich M.C., and B.J. Druker, PNAS, 1/1/2009
• A Unique Case of Adolescent CD56-Negative Extranodal NK/T-CellLymphoma, Nasal Type  
  Chang BH, Stork L, and Fan G, Pediatr Dev Pathol, 1/1/2008
• Management of Menstrual Bleeding and Cycle Control After Hematopoietic Stem Cell Transplant  
  Chang BH, Edelman A, and Godder K, IJGO, 1/1/2008
• Chromosomes with Delayed Replication Timing Lead to Checkpoint Activation, Delayed Recruitment of Aurora B, and Chromosome Instability  
  Chang B.H., Smith L., Huang J., and Thayer T., Oncogene, 1/1/2007
• P300/CBP interacts with ATR and is required for the DNA Replication Checkpoint  
  Stauffer D., Chang B., Huang J., Dunn A., and Thayer T., J Biol Chem, 1/1/2007
• Neuroblastoma found in a 4-year Old after Rituximab Therapy for Opsoclonus Myoclonus  
  Chang B.H., Koch T., Hopkins K., and Malempati S., Pediatric Neurology, 1/1/2006
• Calcium/calmodulin-dependent protein kiinase II inhibitor protein: localization of isoforms in rat brain  
  Chang B.H., Mukherji S., and Soderling T.R., Neuroscience, 1/1/2001
• Cellular signaling through multifunctional Ca2+/calmodulin-dependent protein kinase II  
  Soderling T.R., Chang B.H., and Brickey D., JBC, 1/1/2001
• Ca2+/ calmodulin-dependent kinase II mediates simultaneous enhancement of gap-junctional conductance and glutamatergic transmission  
  Pereda A., Bell T., Chang B.H., Czernik A.J., Nairn A.C., Soderling T.R., and Faber D.S., Proc Natl Acad Sci USA, 1/1/1998
• Characterization of a CaM-KII inhibitory protein in brain  
  Chang B.H., Mukherji S., and Soderling T.R., Proc Natl Acad Sci USA, 1/1/1998
• Identification in the Calcineurin A subunit of the Domain that binds the Regulatory B subunit  
  Watanabe Y., Perrino B.A., Chang B.H., and Soderling T.R., JBC, 1/1/1995
• The essential mitotic target of calmodulin is the 110kD component of the spindle pole body in Saccharomyces cerevisiae  
  Geiser J.R., Sundberg H.A., Chang B.H., Muller E.G.D., and Davis T.N., MCB, 1/1/1993
• Join now to see all

Abstracts/Posters

• Targeting BCL-2 and BCR-ABL1 activity in Ph+ALL.
  Leonard J., Traer E, Hayes-Lattin B, Tyner JW, Druker BJ, & Chang BH, BMT Tandem Meeting, 1/11/2015
• Synergy between targeted BCR-ABL1 and BCL-2 inhibitors is enhanced by the dual SRC/ABL inhibitors in Ph+ Acute lymphoblastic leukemia.
  Leonard J., Traer E., Tyner JW., Hayes-Lattin B., Loriaux M, Druker BJ, & Chang BH, Annual American Society of Clinical Oncology Meeting, Chicago, IL, 1/1/2015
• Dasatinib Shows Therapeutic Potential in the Murine Xenograft Model forTCF3 rearranged Acute Lymphoblastic Leukemia.
  Lenz K, Thompson S, Goloviznina N, Huan J, LaTocha DH, Druker BJ, Tyner JW, Kurre P, & Chang BH, 56th Annual American Society of Hematology Meeting, 1/4/2014
• Coordinate Regulation of Residual Bone Marrow Function in Acute Myeloid Leukemia By Exosomal MicroRNA.
  Hornick NI, Huan J, Goloviznina NA, Cambronne L, Shen R, Chang BH, & Kurre P, 56th Annual American Society of Hematology meeting, 1/4/2014
• Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia.
  Geng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Tyner JW, Chang BH, K..., 56th Annual American Society of Hematology Meeting, 1/4/2014
• Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therape...
  Burke MJ, Brown P, Gore L, Sposto R, Bhojwani D, Chang BH, Dubois SG, Gaynon PS, Glade-Bender J, Heym KM, Sulis ML, Pollard JA, Verma A, & Huynh V, 56th Annual American Society of Hematology Meeting, 1/4/2014
• Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (P...
  Slayton WB, Schultz KR, Jones T, Raetz E, Devidas M, Pulsipher MA, Loh M, Chang BH, Carroll WL, Borowitz MJ, Silverman LB, Brown VI, Winick N, Carroll AJ, Heerema NA, ..., 54th Annual American Society of Hematology meeting, 1/10/2013
• A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymp...
  Cooper TM, Sposto R, Cassar J, Eckroth E, Malvar J, Gaynon P, DuBois S, Chang BH, Gore L, August K, Thomson B, Gammon G, Magoon D, Annesley C, & Brown P, 54th Annual American Society of Hematology meeting, 1/10/2013
• YM155 sensitivity in Pediatric Acute Lymphoblastic Leukemia 2012.
  Chang BH, Jemal A., Tyner JW., Thayer M., Müschen M., & Druker BJ, Annual ASCO Meeting, Chicago, IL, 1/1/2012
• Targeting Survivin with YM155 as a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia.
  Jemal AM., Tyner JW., Thayer M., Muschen M., Druker BJ., & Chang BH, 53rd Annual ASH meeting, 1/10/2011
• Exploring Novel Targets in the Tyrosine Kinase Family in Neuroblastoma.
  Glover J., Chang BH., Tyner J., & Druker BJ, Annual ASHPO Meeting, Baltimore, MD, 1/1/2011
• Exploring Novel Kinase Targets in Neuroblastoma Using Small Molecule Inhibitor Panels.
  Glover J., Chang BH., Tyner J., & Druker BH, Neuroblastoma and Medulloblastoma Translational Research Consortium, Van Andel Institute, Grand Rapids, MI, 1/1/2011
• A High Throughput Kinase Inhibitor Screen Identifies Aurora Kinase Family Sensitivity in Neuroblastoma.
  Glover J., Tyner J.W., Chang B.H., and Druker B.J., COG semi-annual meeting, 1/20/2010
• Small Molecule Inhibitor Panel identifies a new target for dasatinib therapy in pediatric Acute Lymphoblastic Leukemia.
  Chang B.H., Bicocca V., Jemal A., Willis S.G., Druker B.J., Loriaux M., and Tyner J.W., COG semi-annual meeting, 1/20/2010
• ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia.
  Bicocca V, Chang BH, Muschen M, Druker BJ, & Tyner JW, 52nd Annual ASH Meeting, 1/3/2010
• Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia.
  Sanda T, Tyner JW, Gutierrez A, Ngo VN, Moriggl R, Ahn Y, Glover JM, Chang BH, Willis SG, Staudt LM, Druker BJ, & Look AT, 52nd Annual ASH Meeting, 1/3/2010
• RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia.
  Tyner J, Sanda T, Gutierrez A, Glover JM, Chang, BH, Willis SG, Ahn Y, Look AT, and Druker BJ, 52nd Annual ASH Meeting, 1/3/2010
• Functional Screening of the Tyrosine Kinome in Glioblastoma and Astrocytoma Cell Lines.
  Glover J., Tyner J., Chang BH., & Druker BJ, Annual SIOP Meeting, Boston, MA, 1/1/2010
• RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.
  Tyner J.W., Loriaux M., Willis S.G., Chang B.H., Bicocca V.T., Oh S.T., Hollink I.H.I.M., Segers S., DenBoer M.L., van den Heuvel-Eibrink M.M., Zwaan M., Gotlib J.R., ..., 51st Annual ASH Annual Meeting, 1/5/2009
• Mutational Analysis of BCR-Abl from subjects with Relapsed PH+ALL treated on the COG Protocol AALL0031: A Report from the Chilrden’s Oncology Group.
  Chang B.H., Willis S.G, Stork L., Hunger S.P., Carroll W.L., Camitta B.M., Winick N.J., Druker B.J., and Schultz K.R., 51st Annual ASH Annual Meeting, 1/5/2009
• The role of survivin and its potential as a target for therapy in pediatric Philadelphia Chromosome Acute Lymphoblastic.
  Chang B.H., Tyner J, Thayer M, and Druker B.J., National Institute of Child Health and Human Development, Child Health Research Centers Annual Retreat, 1/6/2008
• RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients.
  Tyner J.W., Loriaux M., Willis S.G., Chang B., Bicocca V.T., Oh S., Hollink I.H.I.M., Segers S., den Boer M.L., Zwaan C.M., Gotlib J.R., Deininger M.W.N., and Druker B.J., 50th Annual American Society of Hematology Meeting, San Francisco, CA, 1/6/2008
• Genetic engineering of chromosomes that display a Delay in Replication Timing and a Delay in Mitotic Chromosome Condensation.
  Breger K. S., Smith L., Chang B., and Thayer M., Cancer Genetics and Epigenetics, Gordon Research Conference, Ventura, CA, 1/5/2003
• Characterization of a CaM-KII inhibitory protein in brain.
  Chang B. H., Mukherji S., and Soderling T.R., Cell Calcium, FASEB Summer Research Conference, Snowmass Village, CO, 1/4/1997
• An essential nuclear filament-related protein is a mitotic target of calmodulin.
  Geiser J., Sundberg H., Chang B., and Davis T., Yeast Cell Biology, Cold Spring Harbor, NY, 1/17/1993
• Join now to see all

Lectures

• CAR therapy. 
  Portland, OR - 1/1/2014
• -nibs, -mibs, and –mabs. Modern Cancer Warfare 
  Portland, OR - 1/1/2012
• Recurring cytogenetic abnormalities in Leukemia and their prognostic significance. 
  Portland, OR - 1/1/2012
• Dasatinib Sensitivity in Ph(-)ALL. 
  1/1/2012
• Survivin as a potential target for therapy Pediatric Acute Lymphoblastic Leukemia 
  Philadelphia, PA - 1/1/2010
• Q & A for The Kiwanians 
  Vancouver, WA - 1/1/2010
• The use of siRNA and small molecular inhibitors to identify new targets for therapy in pediatric leukemias: a pilot project using samples from the COG Cell Bank. 
  Dallas, TX - 1/1/2009
• Current Status on Relapsed Leukemias 
  Portland, OR - 1/1/2006
• Common Presentations of Childhood Cancer 
  Portland, OR - 1/1/2004
• Join now to see all

Other

• Cloning and characterization of a novel family of inhibitory proteins of CaM-kinase II. Thesis Dissertation 
  Chang BH, Neuroscience Graduate Program
  1/1/2000